AcelRx Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ACRX Nasdaq 2834 http://www.acelrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for AcelRx Pharmaceuticals Inc

Adamis Announces Appointment of Meera Desai, Ph.D., to Board of Directors - Oct 4th, 2021 11:30 am
AcelRx Pharmaceuticals to Participate in Two September Investor Conferences - Sep 10th, 2021 7:19 pm
Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) - Aug 30th, 2021 9:10 pm
Study Results Announced During Award-Winning Presentation on the Effect of Sufentanil Sublingual Tablet on Outpatient Plastic Surgery at the Annual Miami Cosmetic Surgery Event - Aug 30th, 2021 12:30 pm
Presentation on the Effect of the Administration of Sufentanil Sublingual Tablet on Reducing Post-Operative Recovery Time and Opioid Use in Plastic Surgery at the Annual Miami Cosmetic Surgery Event - Aug 26th, 2021 12:30 pm
21 Stocks Moving in Thursday's Pre-Market Session - Aug 19th, 2021 11:07 am
AcelRx Pharmaceuticals (ACRX) Reports Q2 Loss, Lags Revenue Estimates - Aug 16th, 2021 9:25 pm
AcelRx Pharmaceuticals Reports Second Quarter 2021 Financial Results - Aug 16th, 2021 8:01 pm
Moore Kuehn, PLLC Encourages Investors of ACRX to Contact Law Firm - Aug 12th, 2021 8:01 pm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AcelRx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ACRX - Aug 9th, 2021 8:30 pm
ACRX Last Few Hours to Deadline: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Are Encouraged to Contact Bronstein, Gewirtz & Grossman, LLC - Aug 9th, 2021 5:30 pm
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Aug 9th, 2021 2:16 pm
ACRX Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds AcelRx Pharmaceuticals, Inc. Shareholders of Class Action and Lead Plaintiff Deadline: August 9, 2021 - Aug 9th, 2021 2:00 pm
ACRX Final Deadline Today: Rosen, Trusted National Trial Counsel, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX - Aug 9th, 2021 1:25 pm
AcelRx to Host Second Quarter 2021 Financial Results Call and Webcast on August 16, 2021 - Aug 9th, 2021 12:30 pm
LEAD PLAINTIFF DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm - Aug 9th, 2021 4:20 am
ACRX Final Deadline Tomorrow: Shareholders With Losses Exceeding $50K in AcelRx Pharmaceuticals, Inc. Should Contact Bronstein, Gewirtz & Grossman, LLC - Aug 8th, 2021 5:00 pm
ACRX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Monday Deadline in Securities Class Action – ACRX - Aug 7th, 2021 6:35 pm
AcelRx Pharmaceuticals, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm - Aug 7th, 2021 1:33 am
ACRX Final Deadline Monday: Rosen, a Trusted and Leading Law Firm, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 9 Deadline in Securities Class Action - ACRX - Aug 6th, 2021 11:15 pm